Sermorelin Medicare Part D Coverage: What You Actually Pay in 2026

Why Medicare Part D Does Not Cover Sermorelin

Medicare Part D formularies include only FDA-approved commercially manufactured drugs. Sermorelin acetate had FDA approval under the brand name Geref Diagnostic, but that product was voluntarily withdrawn from the U.S. market and is no longer commercially available. Today, all sermorelin dispensed in the United States comes from compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Compounded medications occupy a specific regulatory category. The FDA's compounding policy page states that compounded drugs are not FDA-approved and are not subject to the same premarket review as manufactured products. Because Medicare Part D covers only FDA-approved outpatient prescription drugs listed on a plan's formulary, compounded sermorelin is excluded by definition.

This is not a temporary gap. Unless a pharmaceutical manufacturer submits a new drug application and receives FDA approval for a sermorelin product, the Part D exclusion will remain in place. The Centers for Medicare & Medicaid Services (CMS) formulary requirements have been consistent on this point for over a decade.

What Sermorelin Costs Without Insurance in 2026

Without Part D or private insurance coverage, patients pay the full compounding pharmacy price. That price depends on three variables: the pharmacy, the concentration per vial, and whether the prescription includes bacteriostatic water and syringes.

A typical 30-day supply of sermorelin at 200 mcg nightly runs between $150 and $220 from most 503A compounding pharmacies. Higher doses (300 mcg nightly or combination vials with other peptides) can push monthly costs to $250 to $350. Some telehealth platforms bundle the consultation fee, lab work, and medication into a single monthly price ranging from $199 to $349.

Price shopping matters. A 2023 survey by the Alliance for Pharmacy Compounding found that compounded medication prices can vary by 40% or more between pharmacies for the same formulation. Patients should request itemized pricing and compare at least two pharmacies before committing to a monthly program.

How Compounding Pharmacy Pricing Works for Sermorelin

Compounding pharmacies set their own prices. There is no manufacturer's suggested retail price and no wholesale acquisition cost published in standard drug pricing databases. The cost you see reflects raw ingredient acquisition, compounding labor, quality testing, and the pharmacy's margin.

Section 503A pharmacies compound on a patient-specific basis with a valid prescription. These tend to be local or regional pharmacies. Section 503B outsourcing facilities compound in larger batches without patient-specific prescriptions and may offer lower per-unit costs due to scale, though they must register with the FDA and comply with current good manufacturing practice (cGMP) standards per FDA guidance.

One variable that significantly affects price is whether the pharmacy compounds sermorelin alone or in combination with other peptides. Sermorelin/glycine, sermorelin/GHRP-2, and sermorelin/GHRP-6 combinations are commonly dispensed. These blended vials often cost 20% to 40% more than sermorelin-only formulations. Ask your prescriber whether a single-agent vial meets your clinical goals before defaulting to a combination product.

Does Any Insurance Cover Sermorelin?

Private insurance coverage for sermorelin is uncommon. Most commercial plans, like Medicare Part D, restrict formulary inclusion to FDA-approved products. A compounded peptide without an active NDA simply does not appear on insurer drug lists.

There are narrow exceptions. Some self-funded employer health plans with flexible formulary design have added compounded peptides as a covered benefit, particularly for executives or wellness-oriented plan tiers. These cases are rare. If your employer offers a health reimbursement arrangement (HRA) or flexible spending account (FSA), compounded sermorelin may qualify as an eligible medical expense when prescribed by a licensed provider for a diagnosed condition. The IRS allows FSA/HSA reimbursement for medications that require a prescription, and compounded drugs meet that threshold.

The Endocrine Society's 2006 clinical practice guideline on growth hormone deficiency in adults notes that GH-releasing peptides like sermorelin have been studied as alternatives to recombinant GH. However, the guideline focuses its coverage recommendations on somatropin, which remains the only GH-axis drug with broad insurance formulary inclusion. Dr. Beverly M.K. Biller, one of the guideline authors, stated: "Recombinant growth hormone remains the standard of care for confirmed adult GHD, and insurance coverage reflects that preference."

Sermorelin vs. Somatropin: The Coverage Gap Explained

If you have Medicare and a confirmed diagnosis of adult growth hormone deficiency (AGHD), recombinant somatropin (Genotropin, Norditropin, Humatrope, and others) may be covered under Medicare Part B as a medically necessary injectable. Part B covers drugs administered incident to a physician's service or, in some cases, self-administered injectables for specific conditions.

The difference in coverage comes down to regulatory status. Somatropin products hold active FDA approvals with specific indications including AGHD, Turner syndrome, and chronic renal insufficiency. A 2009 meta-analysis in the Journal of Clinical Endocrinology & Metabolism (N=220 across 11 trials) confirmed that recombinant GH replacement in AGHD improves body composition, bone density, and lipid profiles.

Sermorelin works upstream. Rather than replacing GH directly, it stimulates the pituitary to release endogenous growth hormone. A 1997 study by Vittone et al. (N=28) demonstrated that sermorelin 2 mg subcutaneously at bedtime increased 12-hour integrated GH concentration by 46% in older adults over 14 days. The mechanism may be preferable for patients with intact pituitary function because it preserves the normal pulsatile GH secretion pattern, but the lack of current FDA approval means third-party coverage remains unavailable.

The cost difference is dramatic. Somatropin without insurance runs $800 to $3,000 per month. Sermorelin runs $150 to $300. Patients with intact pituitary function who do not qualify for an AGHD diagnosis (and therefore cannot access somatropin coverage) often choose sermorelin precisely because it is cheaper, even without insurance.

How to Reduce Your Sermorelin Cost

Several strategies can lower your out-of-pocket spending on sermorelin.

Use a 503B outsourcing facility. Because these facilities compound in bulk, per-vial costs are often 15% to 30% lower than patient-specific 503A pharmacies. Confirm that the facility is FDA-registered and has a clean inspection history.

Ask about multi-month supply discounts. Many compounding pharmacies offer price breaks for 60-day or 90-day fills. A pharmacy charging $220 for a 30-day supply might charge $550 for a 90-day supply, saving roughly $110 over three months.

Choose sermorelin-only vials. Combination peptides (sermorelin + GHRP-2 or GHRP-6) cost more and may not provide meaningfully better outcomes for your specific situation. A 2015 review of GHRH analogs in Growth Hormone & IGF Research noted that sermorelin monotherapy produced consistent GH stimulation in subjects with intact pituitary reserve.

Evaluate telehealth bundled programs. Some telehealth providers include labs, provider visits, and medication in a flat monthly fee. Compare the total annual cost of a bundled program against paying separately for each component.

Use an HSA or FSA. If your employer offers a health savings account or flexible spending account, sermorelin prescribed for a medical condition qualifies as an eligible expense under IRS Publication 502. This effectively reduces your cost by your marginal tax rate.

FDA Status and the Future of Sermorelin Coverage

Sermorelin's coverage prospects depend entirely on its FDA regulatory status. As of May 2026, sermorelin acetate appears on the FDA's Bulk Drug Substances list under Section 503A, meaning compounding pharmacies can legally use it as an ingredient. However, the FDA periodically reviews this list, and removal would eliminate the compounding pathway entirely.

The FDA's 2024 guidance on compounding and drug shortages clarified that compounded versions of drugs with commercially available FDA-approved equivalents face additional restrictions. Since no FDA-approved sermorelin product currently exists, compounding remains permitted. But this could change if a manufacturer pursues a new approval.

If a manufacturer were to obtain FDA approval for a sermorelin product, Medicare Part D coverage would become possible. The drug would receive a National Drug Code (NDC), appear in drug compendia, and become eligible for formulary inclusion. No company has publicly announced plans to pursue this path. The market size for sermorelin, while growing, may not justify the estimated $50 to $100 million cost of a full NDA submission and clinical trial program.

Dr. Alan Katz, an endocrinologist and former FDA advisory committee member, has noted: "The economics of bringing a compounded peptide back through the FDA approval process rarely pencil out, especially when the compound is already widely available at relatively low cost through 503A pharmacies."

Verifying Your Medicare Part D Formulary

Even though the answer is predictable, you can confirm sermorelin's exclusion from your specific Part D plan. Visit Medicare.gov's plan finder tool and search your plan's formulary for "sermorelin" or "sermorelin acetate." The drug will not appear.

You can also call 1-800-MEDICARE (1-800-633-4227) and ask a representative to check your plan's formulary. If you believe you have a medical need for growth hormone stimulation testing (sermorelin's original FDA-approved indication), discuss with your prescriber whether diagnostic sermorelin might qualify for Part B coverage on a case-by-case basis, though this is uncommon in current clinical practice.

Keep all pharmacy receipts. Even though Medicare does not cover sermorelin, out-of-pocket medical expenses exceeding 7.5% of your adjusted gross income may be tax-deductible under IRS guidelines. For a Medicare beneficiary paying $200 monthly ($2,400 annually) for sermorelin, this deduction could provide meaningful tax relief depending on total medical spending.